We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Coronary Imaging Improves Plaques Identification Likely to Cause Future Heart Disease

By HospiMedica International staff writers
Posted on 15 Feb 2011
Findings from a major clinical trial provides new clues into the types of vulnerable plaque that are most likely to cause sudden, unexpected adverse cardiac events, and on the ability to identify them through imaging techniques before they occur.

The trial, Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT), is the first prospective natural history study of atherosclerosis using multimodality imaging to characterize the coronary tree. More...
The study findings were published in the January 20, 2011, issue of the New England Journal of Medicine (NEJM).

"As a result of the PROSPECT trial, we are closer to being able to predict--and therefore prevent--sudden, unexpected adverse cardiac events,” said principal investigator Gregg W. Stone, MD. Dr. Stone is professor of medicine at Columbia University College of Physicians and Surgeons, director of cardiovascular research and Education at the Center for Interventional Vascular Therapy at NewYork Presbyterian Hospital/Columbia University Medical Center (New York, NY, USA).

The multicenter trial examined 700 patients with acute coronary syndromes (ACS) using three-vessel multimodality intracoronary imaging--angiography, gray scale intravascular ultrasound (IVUS), and radiofrequency IVUS--to quantify the clinical event rate due to atherosclerotic progression and to identify those lesions that place patients at risk for unexpected adverse cardiovascular events (sudden death, cardiac arrest, heart attacks, and unstable or progressive angina).

Among the findings of the trial are that most untreated plaques that cause unexpected heart attacks are not mild lesions, as previously thought, but in reality have a large plaque burden and/or a small lumen area. These are characteristics that were invisible to the coronary angiogram but easily identifiable by gray scale IVUS. Moreover, and possibly most significantly, for the first time it was demonstrated that characterization of the underlying plaque composition (with radiofrequency IVUS, also known as VH-IVUS) was able to considerably improve the ability to predict future adverse events beyond other more conventional imaging techniques.

"These results mean that using a combination of imaging modalities, including IVUS to identify lesions with a large plaque burden and/or small lumen area, and VH-IVUS to identify a large necrotic core without a visible cap [a thin cap fibroatheroma] identifies the lesions that are at especially high risk of causing future adverse cardiovascular events,” Dr. Stone said.

Related Links:

NewYork-Presbyterian Hospital/Columbia University Medical Center


Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Vessel Sealing Instrument
ERGOseal
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image: The findings suggest that hematopoietic cell transplantation may benefit patients with Shwachman-Diamond syndrome soon after high-risk features are detected, before advanced malignancy develops. (Image Credit: Shutterstock)

Early Stem Cell Transplantation May Improve Survival in Rare Inherited Bone Marrow Disorder

Shwachman-Diamond syndrome (SDS) is a rare inherited bone marrow disorder that can progress to severe hematologic disease. More than 90% of affected children survive beyond age 20, but fewer than 30% live... Read more

Surgical Techniques

view channel
Image: Memo 4D Curve preserves the mitral annulus’s natural three-dimensional motion while supporting remodeling and is available in sizes up to 42 mm for a broad range of mitral pathology. (Photo courtesy of Corcym)

First Human Implant Performed With New Open Mitral Annuloplasty Ring

In mitral valve repair, clinicians aim to preserve the mitral annulus’s three-dimensional motion while providing enough support for effective remodeling. Ring preferences vary between open and closed ... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.